Subscribe To
VECT / Why Shares of VectivBio Holding Are Up Today
VECT News
By The Motley Fool
May 22, 2023
Why Shares of VectivBio Holding Are Up Today
Ironwood Pharmaceuticals' buyout deal is worth $1 billion. The attraction was VectivBio's late-stage therapy, apraglutide. more_horizontal
By Investors Business Daily
May 22, 2023
VectivBio Stock Catapults 38% After Ironwood Agrees To Buy It For $1 Billion
Ironwood Pharmaceuticals said Monday it will buy VectivBio for $1 billion. The deal sent VECT stock flying, while IRWD stock skidded. more_horizontal
By Barrons
May 22, 2023
Ironwood Pharmaceuticals to Acquire VectivBio for About $1 Billion
Ironwood Pharmaceuticals is paying $17 a share for the Swiss biotech company. more_horizontal
By Market Watch
May 22, 2023
Ironwood Pharmaceuticals to acquire Swiss biotech VectivBio in deal valued at about $1 billion
Ironwood Pharmaceuticals Inc. IRWD, +2.45% said Monday it has agreed to acquire Swiss biotech VectivBio Holding AG VECT, +8.18% for $17 a share in cas more_horizontal
By Seeking Alpha
April 17, 2023
VectivBio: Swiss Company With Excellent Data, Upcoming Catalysts
VectivBio: Swiss Company With Excellent Data, Upcoming Catalysts more_horizontal
By GlobeNewsWire
November 9, 2022
VectivBio to Present at the 2022 Jefferies London Healthcare Conference
BASEL, Switzerland, Nov. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical compan more_horizontal
By Seeking Alpha
April 7, 2022
VectivBio Holding AG (VECT) CEO Luca Santarelli on Q4 2021 Results - Earnings Call Transcript
VectivBio Holding AG (VECT) CEO Luca Santarelli on Q4 2021 Results - Earnings Call Transcript more_horizontal
By GlobeNewsWire
February 8, 2022
VectivBio to Present at the SVB Leerink 11th Annual Global Healthcare Conference
BASEL, Switzerland, Feb. 08, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical compan more_horizontal